Search In this Thesis
   Search In this Thesis  
العنوان
Pelvic angiographic findings in patients with arteriogenic erectile dysfunction :
الناشر
Rasha Abdulaziz Mohammad Zainalabidin ,
المؤلف
Rasha Abdulaziz Mohammad Zainalabidin
هيئة الاعداد
باحث / Rasha Abdulaziz Mohammad Zainalabidin
مشرف / Ihab Abdel-latif Osman
مشرف / Ayman Nihad Moharram
مناقش / Ihab Abdel-latif Osman
تاريخ النشر
2016
عدد الصفحات
138 P. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الأمراض الجلدية
تاريخ الإجازة
26/9/2016
مكان الإجازة
جامعة القاهرة - كلية الطب - Dermatology and andrology
الفهرس
Only 14 pages are availabe for public view

from 152

from 152

Abstract

The aim of the study is to detect pelvic arterial abnormalities in patients with arteriogenic erectile dysfunction and to correlate the presence of these abnormalities with findings of other investigatory methods, also to conduct a trial of revascularization for selected patients. In all, 30 men with arteriogenic ED Non responders to PDE5 inhibitors therapy and post injection max penile systolic velocity <25 cm/s in reported penile duplex ultrasonography were included. Of these, 25 men under go coronary and pelvic angiography after proper preparation and complete personal, medical, sexual history, laboratory testing, local, general and coronary examination, penile duplex study, also the International Index of Erectile Function Questionnaire were taken. Internal pudendal artery abnormalities are an evident finding in almost all patients with arteriogenig ED. Accordingly, PTA of the internal pudendal artery using drug-eluting stent in patients ateriogenic ED, particularly those non responders to PDE5i therapy, seems to be a safe and feasible option to improve arterial inflow, and can result in regaining erectile function.Further randomized controlled studies are needed to assess the efficacy of this new therapeutic modality as compared to the existing therapies. Limitations of the present study include, small sample size, better education for PDE5i use, which may improve patients response, and concomitant management of risk factors. Other groups of patients with versus without CAD or PDE5i responders versus non-responders are targets of future studies